LIGAND PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $6.49B
- P/E (TTM)
- 31.6
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $63.70M | $2.22 | $2.37 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $51.70M | $-0.67 | $1.63 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $59.70M | $2.12 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $115.50M | $5.68 | $3.09 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $47.60M | $0.24 | $1.60 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $45.30M | $-2.21 | $1.33 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $42.80M | $-1.64 | $1.27 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $51.80M | $-0.39 | $1.84 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted earnings per diluted sharenon-GAAP | full year | $9.00 to $9.50 | Raised |
| Adjusted Net Incomenon-GAAP | 2026 | $195.00M to $206.00M | New |
| GAAP Net IncomeGAAP | 2026 | $107.00M to $118.00M | New |
| royalty revenue | Full-year 2026 | $225.00M to $250.00M | Lowered |
| Contract revenue | 2026 | $10.00M to $20.00M | Lowered |
| Total revenue | 2026 | $270.00M to $310.00M | Raised |
| Revenue from sales of Captisol | 2026 | $35.00M to $40.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ligand Pharmaceuticals filed with the SEC
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Regulation FD disclosure · EX-99.1 to Form 8-K
Ligand Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Ligand Announces Closing of Convertible Senior Notes Offering
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Material agreement · Other events · EX-99.1 to Form 8-K
Ligand Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s
Material agreement · Other events · EX-99.1 to Form 8-K
Ligand Acquisition of XOMA Royalty
Material agreement · Other events · EX-99.2 to Form 8-K
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Results of operations · EX-99.1 to Form 8-K
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Ligand Announces Closing of Convertible Senior Notes Offering
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Material agreement · Other events · EX-99.1 to Form 8-K
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Results of operations · EX-99.1 to Form 8-K
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Regulation FD disclosure · EX-99.1 to Form 8-K
Ligand Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Regulation FD disclosure · EX-99.1 to Form 8-K
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
Ligand Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand to Acquire APEIRON Biologics AG for $100 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Ligand Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K/A
Ligand Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Announces Record Date and Details for Distribution for OmniAb
Other events · EX-99.1 to Form 8-K
Ligand Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Analyst Teach - In June 21, 2022 11 am EDT
Regulation FD disclosure · EX-99.1 to Form 8-K
Ligand Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ligand to Spin-Off its OmniAb Business Through Merger with
Other events · EX-99.1 to Form 8-K